The vascular component of alzheimer's disease

Current Neurovascular Research

Volumn 11, Issue 2, 2014, Pages 168-176

  Muresanu, Dafin Fior ^a   Popa Wagner, Aurel ^a,b,f   Stan, Adina ^a   Buga, Ana Maria ^b,f   Popescu, Bogdan Ovidiu ^c,d,e  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d V Babes National Institute of Pathology   (Romania)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^f UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Alzheimer's disease; Neurodegeneration; Neurovascular unit dysfunction; Vascular dementia; Vascular risk factors

Indexed keywords

ABC TRANSPORTER; AMYLOID BETA PROTEIN; ANGIOPOIETIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; GROWTH FACTOR; INSULIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SERUM RESPONSE FACTOR; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1;

AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN DYSFUNCTION; BRAIN PROTECTION; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE RESERVE; GLUCOSE METABOLISM; HUMAN; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE TRACT; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPROTECTION; NEUROTROPHICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR AMYLOIDOSIS; ANIMAL; BRAIN; BRAIN CIRCULATION; METABOLISM; PHYSIOLOGY; VASCULARIZATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; HUMANS;

EID: 84900535662     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611666140408105333     Document Type: Article

References (96)

1. Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci 2012; 322: 2-10.
2. Galasko D. The diagnostic evaluation of a patient with dementia. Continuum (Minneap Minn) 2013; 19: 397-410.
3. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 2009; 5: 649-58.
4. Gorelick PB, Scuteri A, Black SE, et. al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 2672-713.
5. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120: 287-96.
6. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37: 2220-41.
7. Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke 2010; 41(10 Suppl): S144-6.
8. Meguro K, Tanaka N, Nakatsuka M, Nakamura K, Satoh M. Vascular lesions in mixed dementia, vascular dementia, and Alzheimer disease with cerebrovascular disease: the Kurihara Project. J Neurol Sci 2012; 322: 157-60.
9. Dong Y, Gan DZ, Tay SZ, et al. Patterns of neuropsychological impairment in Alzheimer's disease and mixed dementia. J Neurol Sci 2013; 333: 5-8.
10. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148-55.
11. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 2013; 5:17.
12. Muresanu DF, Buzoianu A, Florian SI, von Wild T. Towards a roadmap in brain protection and recovery. J Cell Mol Med 2012; 16: 2861-71.
13. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-60.
14. Enciu AM, Constantinescu SN, Popescu LM, Mureanu DF, Popescu BO. Neurobiology of vascular dementia. J Aging Res 2011; 2011: 401604.
15. MuresanuDF. Neuroprotection and neuroplasticity-a holistic approach and future perspectives. J Neurol Sci 2007; 257:38-43.
16. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
17. Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 2009; 283: 99-106.
18. van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab 2008; 28: 1071-85.
19. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007; 10: 1369-76.
20. Paulson OB, Hasselbalch SG, Rostrup E, Knudsen GM, Pelligrino D. Cerebral blood flow response to functional activation. J Cereb Blood Flow Metab 2010; 30: 2-14.
21. Chow N, Bell RD, Deane R, et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A 2007; 104: 823-8.
22. Sagare AP, Bell RD, Zlokovic BV. Neurovascular dysfunction and faulty amyloid-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(10) pii: a011452.
23. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
24. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease: systematic review and meta-analysis. Neurobiol Aging 2009; 30: 337-52.
25. Kazama K, Anrather J, Zhou P, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADP Hoxidasederived radicals. Circ Res 2004; 95: 1019-26.
26. Faraci FM. Reactive oxygen species: influence on cerebral vascular tone. J Appl Physiol 2006; 100: 739-43.
27. Kitayama J, Faraci FM, Lentz SR, Heistad DD. Cerebral vascular dysfunction during hypercholesterolemia. Stroke 2007; 38: 2136-41.
28. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73: 768e774.
29. McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-deposition in APP/PS1 mice. Neurobiology of Aging 2014; 35: 35:109-21.
30. Mahncke HW, Bronstone A, Merzenich MM. Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Prog Brain Res. 2006; 157: 81-109.
31. Elbaz A, Vicente-Vytopilova P, Tavernier B, et al. Motor function in the elderly: evidence for the reserve hypothesis. Neurology 2013; 81: 417-26.
32. Mercado E 3rd. Neural and cognitive plasticity: from maps to minds. Psychol Bull 2008; 134: 109-37.
33. Devan BD, Pistell PJ, Duffy KB, Kelley-Bell B, Spangler EL, Ingram DK. Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. NeuroRehabilitation 2013, in press.
34. Head E. A canine model of human aging and Alzheimer's disease. Biochim Biophys Acta 2013; 1832: 1384-9.
35. Perez FP, Bose D, Maloney B, Nho K, Shah K, Lahiri DK. Late-Onset Alzheimer's Disease, Heating up and Foxed by Several Proteins:Pathomolecular Effects of the Aging Process. J Alzheimers Dis 2013, in press.
36. Galimberti D, Scarpini E. Progress in Alzheimer's disease research in the last year. J Neurol 2013; 260: 1936-41.
37. Jackson HM, Soto I, Graham LC, Carter GW, Howell GR. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease. BMC Genomics 2013; 14: 831.
38. Katzman R, Aronson M, Fuld P, et al. Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 1989; 25: 317-24.
39. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20:112-7.
40. Tucker AM, Stern Y. Cognitive reserve in aging. Curr Alzheimer Res 2011; 8:354-60.
41. Ferrari C, Nacmias B, Bagnoli S, et al. Imaging and Cognitive Reserve Studies Predict Dementia in Presymptomatic Alzheimer's Disease Subjects. Neurodegener Dis 2014, 13:157-9.
42. Murray AD, Staff RT, McNeil CJ, et al. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. Brain 2011; 134: 3687-96.
43. Qiao J, Lu WH, Wang J, Guo XJ, Qu QM.Vascular Risk Factors Aggravate the Progression of Alzheimer's Disease: A 3-Year Follow-Up Study of Chinese Population. Am J Alzheimers Dis Other Demen. 2014, in press
44. Ewers M, Insel PS, Stern Y, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI). Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology 2013; 80: 1194-201.
45. Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R. Alzheimer's Disease Neuroimaging Initiative. Brain size and the compensation of Alzheimer's disease symptoms: a longitudinal cohort study. Alzheimers Dement 2013; 9: 580-6.
46. Draganski B, Lutti A, Kherif F. Impact of brain aging and neurodegeneration on cognition: evidence from MRI. Curr Opin Neurol 2013; 26: 640-5.
47. Burke MC, Nelson L, Slade JY, et al. Morphometry of the hippocampal microvasculature in post-stroke and age-related dementias. Neuropathol Appl Neurobiol 2013, in press; doi: 10.1111/nan.12085.
48. Pluta R, Jolkkonen J, Cuzzocrea S, et al. Cognitive impairment with vascular impairment and degeneration. Curr Neurovasc Res 2011; 8: 342-50.
49. Gold G, Giannakopoulos P, Herrmann FR, Bouras C, Kövari E. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 2007; 130: 2830-6.
50. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in communitydwelling older persons. Neurology 2007; 69: 2197-204.
51. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovascular disease, beta-amyloid and cognition in aging. Neurobiol Aging 2012; 33: 1006.e25-1006.e36
52. Park JH, Seo SW, Kim C, et al. Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging 2014; 35: 254-60.
53. Lee MJ, Seo SW, Na DL et al.Synergistic Effects of Ischemia and-Amyloid Burden on Cognitive Decline in Patients With Subcortical Vascular Mild Cognitive ImpairmentJAMA Psychiatry, 2014. doi:10.1001/jamapsychiatry.2013.4506
54. Braskie MN, Thompson PM. Understanding cognitive deficits in Alzheimer's disease based on neuroimaging. Trends Cogn Sci 2013; 17: 510-6.
55. Craggs LJ, Hagel C, Kuhlenbaeumer G,et al. Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases. Brain Pathol 2013; 23: 547-57.
56. Craggs LJ, Yamamoto Y, Ihara M, et al. White matter pathology and disconnection in the frontal lobe in CADASIL. Neuropathol Appl Neurobiol 2013, in press.
57. Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009; 118: 115-30.
58. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005; 167: 527-43.
59. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-13.
60. Bell RD, Deane R, Chow N, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009; 11: 143-53.
61. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-90.
62. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004; 41: 193-202.
63. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774.
64. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013; 108: 21-43.
65. Convit A, Wolf OT, Tarshish C, de Leon MJ. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U S A 2003; 100: 2019-22.
66. Emmanuel Y, Cochlin LE, Tyler DJ, de Jager CA, David Smith A, Clarke K. Human hippocampal energy metabolism is impaired during cognitive activity in a lipid infusion model of insulin resistance. Brain Behav 2013; 3: 134-44.
67. Birketvedt GS, Geliebter A, Kristiansen I, Firgenschau Y, Goll R, Florholmen Jr. Diurnal secretion of ghrelin, growth hormone, insulin binding proteins, and prolactin in normal weight and overweight subjects with and without the night eating syndrome. Appetite 2012; 59: 688-92.
68. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science 2010; 328: 321-6.
69. Taekema DG, Ling CH, Blauw GJ, et al. Circulating levels of IGF1 are associated with muscle strength in middle-aged-and oldest-old women. Eur J Endocrinol 2011; 164: 189-96.
70. Cohen AD, Ikonomovic MD, Abrahamson EE, et al. Anti-Amyloid Effects of Small Molecule A-Binding Agents in PS1/APP Mice. Lett Drug Des Discov 2009; 6: 437.
71. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122:1316-38.
72. Agbemenyah HY, Agis-Balboa RC, Burkhardt S, Delalle I, Fischer A. Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiol Dis 2013; 62C: 135-143.
73. Piriz J, Muller A, Trejo JL, Torres-Aleman I. IGF-I and the aging mammalian brain. Exp Gerontol 2011; 46: 96-9.
74. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006; 77: 304-7.
75. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56: 384-402.
76. Xie W, Liang L, Zhao L, et al. Combination of carotid intimamedia thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart 2011; 97: 1326-31.
77. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33.
78. Chen Y, Liang Z, Blanchard J, et al. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 2013; 47: 711-25.
79. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007; 56: 1817-24.
80. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-6.
81. Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 2012; 30: S185-98.
82. Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Flöel A. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 2013; 81: 1746-52.
83. Ohab J, Fleming S, Blesch A, Carmichael S. A neurovascular niche for neurogenesis after stroke. J Neurosci 2006; 26: 13007-16.
84. Cotman CW, Berchtold NC, Christie L-A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 2007; 30: 464-72.
85. Weinstein BM. Vessels and nerves: marching to the same tune. Cell 2005; 120: 299-302.
86. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008; 9: 169-81.
87. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1 beta impairs brain derived neurotrophic factorinduced signal transduction. Neurobiol Aging 2008; 29: 1380-93.
88. Arai K, Lo EH. An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells. J Neurosci 2009; 29: 4351-5.
89. Yang S-P, Bae D-G, Kang HJ, Gwag BJ, Gho YS, Chae CB. Coaccumulation of vascular endothelial growth factor with betaamyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 2004; 25: 283-90.
90. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-9.
91. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56(9):1188-1194.
92. Mansoori N, Tripathi M, Alam R, et al.Serum Folic Acid and RFC A80G Polymorphism in Alzheimer's Disease and VascularDementia. American Journal of Alzheimer's Disease & Other Dementias 2014, 29(1): 38-44.
93. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neuronsand sensitize them to amyloid toxicity in experimental models of Alzheimer'sdisease. J Neurosci. 2002;22(5):1752-1762.
94. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 2009; 118: 87-102.
95. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension 2009; 54: 388-92.
96. Selnes OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol 2006; 2: 538-4.